Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pregnancy and Childbirth
Published in: BMC Pregnancy and Childbirth 1/2020

Open Access 01-12-2020 | Research article

Anti-Müllerian hormone is correlated with cumulative live birth in minimal ovarian stimulation with clomiphene citrate: a retrospective cohort study

Authors: Kenji Ezoe, Xiaowen Ni, Tamotsu Kobayashi, Keiichi Kato

Published in: BMC Pregnancy and Childbirth | Issue 1/2020

Login to get access

Abstract

Background

Several studies have investigated the correlation between the serum anti-Müllerian hormone (AMH) level and in vitro fertilization (IVF) outcomes in controlled ovarian stimulation cycles; however, studies regarding the correlation of the serum AMH level with IVF outcomes in minimal ovarian stimulation cycles remain limited. In this study, we aimed to analyze the correlation of the serum AMH level with ovarian responsiveness, embryonic outcomes, and cumulative live birth rates in clomiphene citrate (CC)-based minimal ovarian stimulation cycles.

Methods

Clinical records of 689 women whose entire ovarian stimulation regimen consisted solely of minimal stimulation cycle IVF using CC alone from November 2017 to October 2019 were retrospectively reviewed. The association between IVF outcomes and the serum AMH level before the initiation of the first fertility treatment was analyzed. Furthermore, the correlation of the serum AMH level with cumulative live birth rates after IVF treatment was assessed. The Cochran-Armitage test, Pearson’s chi-squared test, Spearman rank correlation test, Student’s t-test, one-way analysis of variance, logistic regression analysis, Kaplan-Meier method and Cox proportional hazards model were used to analyze the data.

Results

The serum AMH level positively correlated with the number of retrieved oocytes, blastocyst formation rate, blastocyst cryopreservation rate, and live birth rate per oocyte retrieval in CC-based minimal ovarian stimulation cycles without any exogenous gonadotropin administration. Furthermore, the cumulative live birth rate and treatment period required for conceiving were strongly associated with the serum AMH level at the initiation of fertility treatment.

Conclusions

A low serum AMH level correlated with low ovarian responsiveness, impaired pre-implantation embryonic development, and decreased cumulative live birth rate in CC-based minimal ovarian stimulation cycles. Therefore, the cycle success rate would be predicted by measuring the serum AMH level in minimal ovarian stimulation with CC alone.
Appendix
Available only for authorised users
Literature
1.
Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10(2):77–83 Epub 2004/01/27.PubMedCrossRef
2.
Jeppesen JV, Anderson RA, Kelsey TW, Christiansen SL, Kristensen SG, Jayaprakasan K, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod. 2013;19(8):519–27 Epub 2013/04/09.PubMedCrossRef
3.
Themmen AP. Anti-Mullerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. J Natl Cancer Inst Monogr. 2005;34:18–21 Epub 2005/03/24.CrossRef
4.
Visser JA, Themmen AP. Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234(1–2):81–6 Epub 2005/04/20.PubMedCrossRef
5.
La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21(12):3103–7 Epub 2006/08/23.PubMedCrossRef
6.
Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;91(10):4057–63 Epub 2006/06/29.PubMedCrossRef
7.
Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod. 2007;22(7):1837–40 Epub 2007/05/09.PubMedCrossRef
8.
Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008;90(2):395–400 Epub 2007/10/09.PubMedCrossRef
9.
La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–30 Epub 2009/10/02.PubMedCrossRef
10.
Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93(9):3478–83 Epub 2008/07/03.PubMedPubMedCentralCrossRef
11.
van Disseldorp J, Faddy MJ, Themmen AP, de Jong FH, Peeters PH, van der Schouw YT, et al. Relationship of serum antimullerian hormone concentration to age at menopause. J Clin Endocrinol Metab. 2008;93(6):2129–34 Epub 2008/03/13.PubMedCrossRef
12.
Wu CH, Chen YC, Wu HH, Yang JG, Chang YJ, Tsai HD. Serum anti-Mullerian hormone predicts ovarian response and cycle outcome in IVF patients. J Assist Reprod Genet. 2009;26(7):383–9 Epub 2009/09/22.PubMedPubMedCentralCrossRef
13.
Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002;77(3):468–71 Epub 2002/03/02.PubMedCrossRef
14.
Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod. 2006;21(1):159–63 Epub 2005/08/27.PubMedCrossRef
15.
Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. Hum Reprod. 2007;22(9):2414–21 Epub 2007/07/20.PubMedCrossRef
16.
Wunder DM, Bersinger NA, Yared M, Kretschmer R, Birkhauser MH. Statistically significant changes of antimullerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril. 2008;89(4):927–33 Epub 2007/07/03.PubMedCrossRef
17.
Arce JC, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril. 2013;99(6):1644–53 Epub 2013/02/12.PubMedCrossRef
18.
Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Antimullerian hormone levels are strongly associated with live-birth rates after assisted reproduction. J Clin Endocrinol Metab. 2013;98(3):1107–14 Epub 2013/02/15.PubMedCrossRef
19.
Steiner AZ, Pritchard D, Stanczyk FZ, Kesner JS, Meadows JW, Herring AH, et al. Association between biomarkers of Ovarian reserve and infertility among older women of reproductive age. Jama. 2017;318(14):1367–76 Epub 2017/10/20.PubMedPubMedCentralCrossRef
20.
Song D, Shi Y, Zhong Y, Meng Q, Hou S, Li H. Efficiency of mild ovarian stimulation with clomiphene on poor ovarian responders during IVF\ICSI procedures: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2016;204:36–43 Epub 2016/08/16.PubMedCrossRef
21.
Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 1997;3(4):359–65 Epub 1997/07/01.PubMedCrossRef
22.
Zhang JJ, Merhi Z, Yang M, Bodri D, Chavez-Badiola A, Repping S, et al. Minimal stimulation IVF vs conventional IVF: a randomized controlled trial. Am J Obstet Gynecol. 2016;214(1):96 e1–8 Epub 2015/08/12.CrossRef
23.
Bodri D, Kawachiya S, De Brucker M, Tournaye H, Kondo M, Kato R, et al. Cumulative success rates following mild IVF in unselected infertile patients: a 3-year, single-Centre cohort study. Reprod BioMed Online. 2014;28(5):572–81 Epub 2014/03/19.PubMedCrossRef
24.
Flisser E, Copperman AB. Why do couples drop-out from IVF treatment? Hum Reprod. 2009;24(3):758–9 author reply 9. Epub 2008/12/17.PubMedCrossRef
25.
Verberg MF, Eijkemans MJ, Macklon NS, Heijnen EM, Baart EB, Hohmann FP, et al. The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis. Hum Reprod Update. 2009;15(1):5–12 Epub 2008/12/19.PubMedCrossRef
26.
Verberg MF, Macklon NS, Nargund G, Frydman R, Devroey P, Broekmans FJ, et al. Mild ovarian stimulation for IVF. Hum Reprod Update. 2009;15(1):13–29 Epub 2008/12/19.PubMedCrossRef
27.
Figueiredo JB, Nastri CO, Vieira AD, Martins WP. Clomiphene combined with gonadotropins and GnRH antagonist versus conventional controlled ovarian hyperstimulation without clomiphene in women undergoing assisted reproductive techniques: systematic review and meta-analysis. Arch Gynecol Obstet. 2013;287(4):779–90 Epub 2012/12/20.PubMedCrossRef
28.
Gibreel A, Maheshwari A, Bhattacharya S. Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database Syst Rev. 2012;11:CD008528 Epub 2012/11/16.PubMed
29.
Ovarian Stimulation T, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI (dagger). Hum Reprod Open. 2020;2020(2):hoaa009 Epub 2020/05/13.PubMedCrossRef
30.
Ezoe K, Hickman C, Miki T, Okimura T, Uchiyama K, Yabuuchi A, et al. Cytoplasmic halo characteristics during fertilization and their implications for human preimplantation embryo development and pregnancy outcome. Reprod BioMed Online. 2020;41(2):191–202 Epub 2020/06/17.PubMedCrossRef
31.
Kato K, Ezoe K, Yabuuchi A, Fukuda J, Kuroda T, Ueno S, et al. Comparison of pregnancy outcomes following fresh and electively frozen single blastocyst transfer in natural cycle and clomiphene-stimulated IVF cycles. Hum Reprod Open. 2018;2018(3):hoy006 Epub 2019/03/22.PubMedPubMedCentralCrossRef
32.
Ezoe K, Ohata K, Morita H, Ueno S, Miki T, Okimura T, et al. Prolonged blastomere movement induced by the delay of pronuclear fading and first cell division adversely affects pregnancy outcomes after fresh embryo transfer on day 2: a time-lapse study. Reprod BioMed Online. 2019;38(5):659–68 Epub 2019/03/12.PubMedCrossRef
33.
Ohata K, Ezoe K, Miki T, Morita H, Tsuchiya R, Kaneko S, et al. Blastomere movement post first cell division correlates with embryonic compaction and subsequent blastocyst formation. Reprod Biol Endocrinol. 2019;17(1):44 Epub 2019/05/17.PubMedPubMedCentralCrossRef
34.
Veeck LL. In: Veeck LL, editor. Abnormal morphology of human oocytes and conceptus. Atlas of the human oocyte and early conceptus. 2nd ed. Baltimore: Williams & Wilkins; 1996.
35.
Gardner D, Schoolcraft W. In vitro culture of human blastocysts. Jansen R, editor. Carnforth: Parthenon Publishing; 1999.
36.
Mori C, Yabuuchi A, Ezoe K, Murata N, Takayama Y, Okimura T, et al. Hydroxypropyl cellulose as an option for supplementation of cryoprotectant solutions for embryo vitrification in human assisted reproductive technologies. Reprod BioMed Online. 2015;30(6):613–21 Epub 2015/04/22.PubMedCrossRef
37.
Kato K, Takehara Y, Segawa T, Kawachiya S, Okuno T, Kobayashi T, et al. Minimal ovarian stimulation combined with elective single embryo transfer policy: age-specific results of a large, single-Centre, Japanese cohort. Reprod Biol Endocrinol. 2012;10:35 Epub 2012/05/01.PubMedPubMedCentralCrossRef
38.
Fukuda J, Abe T, Okuno T, Kobayashi T, Kato K. Administering human chorionic gonadotropin injections for triggering follicle maturation could impact fertility during the subsequent menstrual cycle. Int J Gynaecol Obstet. 2016;132(3):309–13 Epub 2015/12/09.PubMedCrossRef
39.
Karakida S, Ezoe K, Fukuda J, Yabuuchi A, Kobayashi T, Kato K. Effects of gonadotropin administration on clinical outcomes in clomiphene citrate-based minimal stimulation cycle IVF. Reprod Med Biol. 2020;19(2):128–34 Epub 2020/04/11.PubMedCrossRef
40.
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82(5):1323–9 Epub 2004/11/10.PubMedCrossRef
41.
Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21(8):2022–6 Epub 2006/05/09.PubMedCrossRef
42.
Cupisti S, Dittrich R, Mueller A, Strick R, Stiegler E, Binder H, et al. Correlations between anti-mullerian hormone, inhibin B, and activin a in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes. Eur J Med Res. 2007;12(12):604–8 Epub 2007/11/21.PubMed
43.
Fanchin R, Mendez Lozano DH, Frydman N, Gougeon A, di Clemente N, Frydman R, et al. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab. 2007;92(5):1796–802 Epub 2007/03/01.PubMedCrossRef
44.
Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Mullerian hormone as a predictor of IVF outcome. Reprod BioMed Online. 2007;14(5):602–10 Epub 2007/05/19.PubMedCrossRef
45.
Wang S, Zhang Y, Mensah V, Huber WJ 3rd, Huang YT, Alvero R. Discordant anti-mullerian hormone (AMH) and follicle stimulating hormone (FSH) among women undergoing in vitro fertilization (IVF): which one is the better predictor for live birth? J Ovarian Res. 2018;11(1):60 Epub 2018/07/18.PubMedPubMedCentralCrossRef
46.
Shahrokh Tehraninezhad E, Mehrabi F, Taati R, Kalantar V, Aziminekoo E, Tarafdari A. Analysis of ovarian reserve markers (AMH, FSH, AFC) in different age strata in IVF/ICSI patients. Int J Reprod Biomed (Yazd). 2016;14(8):501–6 Epub 2016/09/30.CrossRef
47.
Lukaszuk K, Kunicki M, Liss J, Bednarowska A, Jakiel G. Probability of live birth in women with extremely low anti-Mullerian hormone concentrations. Reprod BioMed Online. 2014;28(1):64–9 Epub 2013/11/26.PubMedCrossRef
48.
Goswami M, Nikolaou D. Is AMH level, independent of age, a predictor of live birth in IVF? J Hum Reprod Sci. 2017;10(1):24–30 Epub 2017/05/10.PubMedPubMedCentral
49.
Li HW, Lee VC, Lau EY, Yeung WS, Ho PC, Ng EH. Ovarian response and cumulative live birth rate of women undergoing in-vitro fertilisation who had discordant anti-Mullerian hormone and antral follicle count measurements: a retrospective study. PLoS One. 2014;9(10):e108493 Epub 2014/10/15.PubMedPubMedCentralCrossRef
50.
Leijdekkers JA, Eijkemans MJC, van Tilborg TC, Oudshoorn SC, McLernon DJ, Bhattacharya S, et al. Predicting the cumulative chance of live birth over multiple complete cycles of in vitro fertilization: an external validation study. Hum Reprod. 2018;33(9):1684–95 Epub 2018/08/08.PubMedCrossRef
51.
Li HW, Lee VC, Lau EY, Yeung WS, Ho PC, Ng EH. Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis. PLoS One. 2013;8(4):e61095 Epub 2013/05/03.PubMedPubMedCentralCrossRef
52.
Hamdine O, Eijkemans MJC, Lentjes EGW, Torrance HL, Macklon NS, Fauser B, et al. Antimullerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization. Fertil Steril. 2015;104(4):891–8 e2. Epub 2015/07/22.PubMedCrossRef
Metadata
Title
Anti-Müllerian hormone is correlated with cumulative live birth in minimal ovarian stimulation with clomiphene citrate: a retrospective cohort study
Authors
Kenji Ezoe
Xiaowen Ni
Tamotsu Kobayashi
Keiichi Kato
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pregnancy and Childbirth / Issue 1/2020
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-020-03446-1

Other articles of this Issue 1/2020

BMC Pregnancy and Childbirth 1/2020 Go to the issue

Research article

Fetal sex and maternal insulin resistance during mid-pregnancy: a retrospective cohort study

Case report

Use of balloon tamponade in management of vaginal laceration and its possible complication of urinary stress incontinence: a case report

Research article

Antenatal depression and anxiety and early pregnancy BMI among White British and South Asian women: retrospective analysis of data from the Born in Bradford cohort

Research article

Health management committee strengthening and community mobilisation through women’s groups to improve trained health worker attendance at birth in rural Nepal: a cluster randomised controlled trial

Research article

Results-based financing to increase uptake of skilled delivery services in The Gambia: using the ‘three delays’ model to interpret midline evaluation findings

Research article

Spatio-temporal distribution and associated factors of home delivery in Ethiopia. Further multilevel and spatial analysis of Ethiopian demographic and health surveys 2005–2016